With increasing cancer prevalence, the Minimal Residual Disease Testing Market is poised for substantial growth over the next decade. Advanced molecular diagnostics, Europe and North America continue to lead in technological adoption, whereas emerging economies show promising growth potential due to rising healthcare investments. Continuous R&D and regulatory approvals are...